Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Matthew R. Hayes, Tito Borner, Bart C. De Jonghe
Diabetes (2021) Vol. 70, Iss. 9, pp. 1956-1961
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 700
Obesity: A Review of Pathophysiology and Classification
Bradley Busebee, Wissam Ghusn, Lizeth Cifuentes, et al.
Mayo Clinic Proceedings (2023) Vol. 98, Iss. 12, pp. 1842-1857
Open Access | Times Cited: 48
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Nanoparticle enrichment mass-spectrometry proteomics identifies protein-altering variants for precise pQTL mapping
Karsten Suhre, Guhan Venkataraman, Harendra Guturu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 48
GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
Ricardo J. Samms, Richard Cosgrove, Brandy M. Snider, et al.
Diabetes (2022) Vol. 71, Iss. 7, pp. 1410-1423
Open Access | Times Cited: 41
Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding
Alice E. Adriaenssens, Johannes Broichhagen, Anne de Bray, et al.
JCI Insight (2023) Vol. 8, Iss. 10
Open Access | Times Cited: 30
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
Xavier Morató, Vanesa Pytel, Sara Jofresa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9305-9305
Open Access | Times Cited: 33
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
Juan P. Frías, Martin L. Lee, Matthew M. Carter, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 5, pp. 1203-1212
Open Access | Times Cited: 15
The antiemetic actions of GIP receptor agonism
Tito Borner, Bart C. De Jonghe, Matthew R. Hayes
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 4, pp. E528-E536
Closed Access | Times Cited: 5
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis, Jun‐Li Liu, Μaria Dalamaga
Metabolism Open (2022) Vol. 16, pp. 100220-100220
Open Access | Times Cited: 21
Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats
Rae J. Herman, Matthew R. Hayes, Janet Audrain‐McGovern, et al.
Psychopharmacology (2023) Vol. 240, Iss. 6, pp. 1373-1386
Closed Access | Times Cited: 12
The role of incretin receptor agonists in the treatment of obesity
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 4
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients
Mary R. Shen, Kwadwo Owusu-Boaitey, Laura M. Holsen, et al.
Journal of Addiction Medicine (2024) Vol. 18, Iss. 5, pp. 488-498
Closed Access | Times Cited: 4
The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
Jonathan D. Douros, Jonathan N. Flak, Patrick J. Knerr
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Klaudia Nowak, Krzysztof Łupina, Anna Romac, et al.
Annals of Pharmacotherapy (2025)
Closed Access
Enfin libéré(e) de la nourriture ?
Lauren J. Young
Cerveau & Psycho (2025) Vol. Nº 174, Iss. 3, pp. 72-79
Closed Access
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Jennifer M. Kaplan, Adnin Zaman, Layla A. Abushamat
Current Cardiology Reports (2024) Vol. 26, Iss. 9, pp. 1011-1019
Closed Access | Times Cited: 3
The role of cereal soluble fiber in the beneficial modulation of glycometabolic gastrointestinal hormones
Stefan Kabisch, Martin O. Weickert, A. Pfeiffer
Critical Reviews in Food Science and Nutrition (2022) Vol. 64, Iss. 13, pp. 4331-4347
Open Access | Times Cited: 12
Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
Zhimin Xu, Song Wen, Meiyuan Dong, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases
Sulayman A. Lyons, Jacqueline L. Beaudry
Endocrinology (2023) Vol. 164, Iss. 11
Open Access | Times Cited: 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt
Peptides (2024) Vol. 174, pp. 171168-171168
Closed Access | Times Cited: 1
Safety of native glucose-dependent insulinotropic polypeptide in humans
Mads M. Helsted, Nina L. Schaltz, Lærke S. Gasbjerg, et al.
Peptides (2024) Vol. 177, pp. 171214-171214
Closed Access | Times Cited: 1
The role of m6A modification in the risk prediction and Notch1 pathway of Alzheimer’s disease
Yingdan Qiao, Yingna Mei, Minqi Xia, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110235-110235
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top